NCT05824663View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

HBM1020

Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.

Sponsors
All Listed Sponsors
lead

Harbour BioMed US, Inc.

INDUSTRY